Experimental drug for moderate to severe ulcerative colitis
Part of Digestive system clinical trials.
This trial tests an experimental medication (tilpisertib fosmecarbil) for people with moderate to severe ulcerative colitis who have already tried at least one advanced therapy but it didn't work well enough. The study aims to see if this new drug can help reduce inflammation and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have had ulcerative colitis for at least 90 days, with inflammation reaching at least 15 cm from the anal opening.
- Your disease must be moderately to severely active, as shown by symptoms like frequent stools, bleeding, and a certain score from an endoscopy.
- You must have tried at least one advanced treatment (like a biologic) for your colitis, but it stopped working or didn't work well enough.
- You must not have had any serious infections requiring hospital care or IV antibiotics in the last 8 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two experimental drugs, Eltrekibart and Mirikizumab, for adults with moderate to severe ulcerative colitis who have not responded well to other treatments. The goal is to see if these drugs can help control the disease.
This study tests a new medication called BI 3032950 for people with ulcerative colitis who have already tried other advanced treatments (biologics or targeted therapies) that didn't work well enough or caused problems. The goal is to see if the new drug is safe and helps control inflammation in the colon.
This trial tests an experimental drug (ISM5411) for people with active ulcerative colitis. The goal is to see if the drug can reduce inflammation and improve symptoms.
This trial tests a new treatment for people with ulcerative colitis (UC) whose disease is active despite taking only mesalamine or sulfasalazine. It aims to find a therapy that can reduce inflammation and improve symptoms.
This study tests an investigational medication called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It's for people who have tried other treatments without success. The goal is to see if the drug can reduce inflammation and improve symptoms.
This trial is testing multiple new drugs for people with moderate to severe ulcerative colitis or Crohn's disease who have not had success with at least one standard treatment. The goal is to find a better option that can help control symptoms and inflammation.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.